GRCE — Grace Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1444192 ·
Last close
$2.08
Market Cap
$43.75M
52W High
$5.18
52W Low
$1.79
ADV30
135,593
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,384,000 | -15,790,000 | 50,073,000 | 13,756,000 | 1,862,000 |
| Mar 2026 | 0 | — | -3,010,000 | -1,178,000 | 66,654,000 | 16,977,000 | 2,758,000 |
| Dec 2025 | 0 | — | -2,449,000 | -2,315,000 | 68,488,000 | 18,672,000 | 3,596,000 |
| Sep 2025 | 0 | — | -2,529,000 | -938,000 | 66,576,000 | 16,862,000 | 3,758,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,869,000
Investing CF
$0
Financing CF
$3,713,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.77
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-228,480,000
Inventory
—
Receivables
$20,000
ST Investments
—
EBIT TTM
$-11,078,000
Pretax Income TTM
$-9,493,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -11,077,000 | -7,793,000 | 66,654,000 | 2,758,000 | 63,896,000 | -8,869,000 |
| Mar 2025 | 0 | -16,679,000 | -9,568,000 | 71,993,000 | 5,383,000 | 66,610,000 | -14,904,000 |
| Mar 2024 | 0 | -11,367,000 | -12,853,000 | 73,300,000 | 11,557,000 | 61,743,000 | -12,333,000 |
| Mar 2023 | 0 | -18,247,000 | -42,429,000 | 79,123,000 | 11,168,000 | 67,955,000 | -15,913,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$685,000
NetIncome TTM
$-7,793,000
OpCashFlow TTM
—
Assets (Latest)
$68,488,000
Forward EPS
$-0.46
Max Pain — expiry 2026-11-20
max pain strike: $2.50 · spot: $2.08 · call oi: 2,727 · put oi: 127
Expected Move to 2026-11-20:
±$0.58
(27.64%) —
implied range
$1.50 –
$2.66
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRRUF | IMMUTEP Ltd | $44.21M | $0.03 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $42.17M | $2.87 | — |
| VERU | VERU INC. | $41.94M | $2.46 | — |
| NSRX | Nasus Pharma Ltd | $41.12M | $3.51 | — |
| SCYX | SCYNEXIS INC | $40.59M | $4.08 | — |
News headlines (Yahoo Finance, 1h cache)
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
2026-09-03 12:00 · Yahoo
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
2026-08-13 12:00 · Yahoo
Grace Therapeutics Announces $10 Million Private Placement
2026-08-05 01:00 · Yahoo
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
2026-07-28 11:00 · Yahoo
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
2026-06-18 12:00 · Yahoo
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
2026-04-23 17:13 · Yahoo
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
2026-04-14 12:00 · Yahoo
We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate
2026-04-04 13:52 · Yahoo
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
2026-03-19 12:00 · Yahoo
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
2026-02-25 13:00 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-10-05 18:46:05 | 2026-10-01 | Opaleye Management Inc. | 10% | P - Purchase | 2.05 | 60490 | 123819 |